Patents by Inventor Mark DeBenedette
Mark DeBenedette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11779599Abstract: This invention provides methods of evaluating immune system parameters to identify and treat patients who are likely to experience more favorable treatment outcomes. This invention also provides methods for treating a human patient with a dendritic cell therapy by obtaining at least one value or measurement of the level and/or amount of a particular type of treatment indicator in the patient, confirming that said value or measurement exceeds or is less than the treatment threshold value for that value or measurement, and administering said dendritic cell therapy to the patient.Type: GrantFiled: November 7, 2018Date of Patent: October 10, 2023Assignee: COIMMUNE, INC.Inventors: Charles Nicolette, Mark Debenedette, Joseph Horvatinovich, Alex Dusek, Tamara Monesmith
-
Publication number: 20230061319Abstract: The present disclosure provides methods of treating a tumor (e.g., renal cell cancer) by administering an immunotherapy comprising dendritic cells loaded with RNA encoding a tumor antigen and a pharmaceutical which can decrease circulating IgG levels, block IgG-mediated activation of CD16+ T cells, decrease the concentration and/or function of B cells, reduce the frequency of CD38+ TGF-?+ B cells, decrease B cell secretion of TGF-?, and/or sustain the frequency of CD25+CD28+ CD4 and/or CD8 T cells.Type: ApplicationFiled: January 8, 2021Publication date: March 2, 2023Inventors: Joseph HORVATINOVICH, Mark DEBENEDETTE, Charles NICOLETTE, Irina TCHEREPANOVA
-
Publication number: 20210317410Abstract: The present invention relates to Natural Killer (“NK”) cells and uses thereof. In some embodiments NK cells are generated in vitro and used for adoptive transfer therapy. In some embodiments NK cells are generated in vivo to stimulate a patient's immune response.Type: ApplicationFiled: May 24, 2019Publication date: October 14, 2021Inventors: Mark DEBENEDETTE, Joseph HORVATINOVICH, Charles NICOLETTE
-
Publication number: 20210030791Abstract: This invention provides methods of evaluating immune system parameters to identify and treat patients who are likely to experience more favorable treatment outcomes. This invention also provides methods for treating a human patient with a dendritic cell therapy by obtaining at least one value or measurement of the level and/or amount of a particular type of treatment indicator in the patient, confirming that said value or measurement exceeds or is less than the treatment threshold value for that value or measurement, and administering said dendritic cell therapy to the patient.Type: ApplicationFiled: November 7, 2018Publication date: February 4, 2021Inventors: Charles NICOLETTE, Mark DEBENEDETTE, Joseph HORVATINOVICH, Alex DUSEK, Tamara MONESMITH
-
Publication number: 20190315878Abstract: Antibodies are provided that alter the TLR4 signaling pathway to produce an immunosuppressive effect. The antibodies are useful for the treatment or prevention of an unwanted immune response in a subject, such as autoimmune disease, transplant rejection, and allergic reactions.Type: ApplicationFiled: November 3, 2017Publication date: October 17, 2019Inventors: Charles NICOLETTE, Mark DEBENEDETTE, Joseph HORVATINOVICH
-
Patent number: 10184108Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: December 19, 2016Date of Patent: January 22, 2019Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark Debenedette
-
Publication number: 20170096639Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: December 19, 2016Publication date: April 6, 2017Inventors: Don HEALEY, Irina Tcherepanova, Melissa Adams, Mark Debenedette
-
Publication number: 20170065690Abstract: The present invention relates to TSCM cells and uses thereof. TSCM cells can be used help identify and treat patients who are likely to experience particular treatment outcomes. In other embodiments TSCM cells are generated in vitro and used for adoptive transfer therapy.Type: ApplicationFiled: February 20, 2015Publication date: March 9, 2017Inventors: Mark DeBenedette, Charles Nicolette, Joseph Horvatinovich
-
Patent number: 9523077Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: July 15, 2013Date of Patent: December 20, 2016Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark DeBenedette
-
Publication number: 20160151473Abstract: The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response.Type: ApplicationFiled: January 29, 2016Publication date: June 2, 2016Inventors: David E. Spaner, Neil Berinstein, Mark DeBenedette, Igor Astasturov, Teresa Petrella, Umit Bagriacik, Gail Lumber, Neill Iscoe, Caitlin Hammond, Paul Hamilton
-
Publication number: 20140017788Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: July 15, 2013Publication date: January 16, 2014Applicant: ARGOS THERAPEUTICS, INC.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark DeBenedette
-
Publication number: 20120269832Abstract: This invention provides novel CD40L polypeptides and nucleic acids, as well as antigen presenting cells and vaccines comprising such CD40L polypeptides and/or nucleic acids, and related methods for preparing the antigen presenting cells and vaccines. The antigen presenting cells and vaccines are useful for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention.Type: ApplicationFiled: April 6, 2007Publication date: October 25, 2012Inventors: Donald Healey, Irina Tcherepanova, Atsushi Hinohara, Melissa Adams, Mark DeBenedette
-
Publication number: 20070082400Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: April 7, 2006Publication date: April 12, 2007Inventors: Donald Healey, Irina Tcherepanova, Melissa Adams, Atsushi Hinohara, Mark DeBenedette
-
Publication number: 20040223949Abstract: The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response.Type: ApplicationFiled: October 21, 2003Publication date: November 11, 2004Applicant: Sunnybrook and Women's College Health Sciences Center Aventis Pasteur, Ltd.Inventors: Igor Astsaturov, Teresa Petrella, Mark DeBenedette, Neil Berinstein, David E. Spaner